The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances - Yahoo Finance

The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances

First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations

Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time.

The BPC-157 patch is currently in active testing, with results anticipated in the near term. Subject to the satisfactory completion of these testing milestones, the Company intends to progress the product closer to commercial release as part of The Precision Peptide Company's product portfolio.

For decades, the peptide category has been gated by the needle. While interest in peptides has grown rapidly across recovery, longevity, and broader wellness, the majority of consumers have never crossed the threshold into the category - research consistently identifies needle aversion as a leading barrier to therapies that consumers would otherwise consider. Adoption has therefore skewed toward biohackers, athletes, and clinical populations already comfortable with self-administered injectables.

The innovative patch is designed to remove that barrier entirely. Worn directly on the skin and precision-engineered for controlled, sustained peptide delivery, the patch eliminates the reconstitution, sterile handling, and dose measurement associated with injectable peptide therapies. The result is a wearable, mainstream-ready format intended to bring BPC-157 and other formulas to consumers who have followed the rise of peptides from a distance and have been waiting for a delivery format they would actually use.

Pratap Sandhu, CEO of The Precision Peptide Company, commented:

"This is the product that brings peptides into the mainstream. The needle has historically been the single biggest barrier to entry for this category, and removing it fundamentally changes who the customer is. The patch is built for the person who has read the headlines, listened to the podcasts, and decided peptides aren't for them because they aren't willing to inject. We believe it is the bridge between where peptides have come from and the far larger consumer market they can serve, and the progression of testing to date supports our confidence in that path."